• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumour biology : >Platelet VEGF and serum TGF-beta 1 levels predict chemotherapy response in non-small cell lung cancer patients
【24h】

Platelet VEGF and serum TGF-beta 1 levels predict chemotherapy response in non-small cell lung cancer patients

机译：血小板VEGF和血清TGF-β1水平可预测非小细胞肺癌患者的化疗反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We examined the levels of platelet vascular endothelial growth factor (VEGF(PLT)) and serum level of transforming growth factor beta 1 (TGF-beta 1) in non-small cell lung cancer (NSCLC) patients before and after chemotherapy to assess their clinical value as biomarkers. A total of 115 subjects were recruited at the First Hospital of Qinhuangdao between July 2012 and October 2013, including 65 NSCLC patients receiving chemotherapy (NSCLC group) and 50 healthy controls (control group). All NSCLC patients received gemcitabine plus cisplatin (GP regimen) for a total of two courses. VEGF(PLT) and serum TGF-beta 1 levels were measured before and after chemotherapy using enzyme-linked immunosorbent assay (ELISA). Platelet count was obtained using the Abbott CD-1600 auto blood analyzer. NSCLC group was categorized into complete response (CR) plus partial response (PR) group and stable disease (SD) plus progressive disease (PD) group based on the results of CT scans obtained 1 week after chemotherapy. Our results revealed that VEGF(PLT) and serum TGF-beta 1 levels were significantly higher in NSCLC group before chemotherapy, compared to the control group (VEGF(PLT), 0.813 +/- 0.072 vs. 0.547 +/- 0.024; t = 26.48; P < 0.001 and TGF-beta 1, 46.00 +/- 4.47 vs. 16.43 +/- 2.12; t = 44.87; P < 0.001). Importantly, VEGF(PLT) and serum TGF-beta 1 levels decreased significantly after chemotherapy in CR + PR group in comparison with before chemotherapy (VEGF(PLT), 0.453 +/- 0.078 vs. 0.814 +/- 0.127; t = 15.51; P < 0.001 and TGF-beta 1, 20.17 +/- 2.43 vs. 42.13 +/- 4.54; t = 27.31; P < 0.001). By contrast, VEGF(PLT) and serum TGF-beta 1 levels were markedly higher after chemotherapy in the SD + PD group in comparison with before chemotherapy (VEGF(PLT), 0.816 +/- 0.043 vs. 1.065 +/- 0.016; t = 22.38; P < 0.001 and TGF-beta 1, 41.80 +/- 5.46 vs. 45.83 +/- 4.62; t = 2.32; P = 0. 03). Our results show that NSCLC patients exhibit high VEGF(PLT) and serum TGF-beta 1 levels, and VEGF(PLT) and TGF-beta 1 levels correlate with chemotherapy response to GP regimen. Therefore, VEGF(PLT) and serum TGF-beta 1 levels are valuable biomarkers in clinical monitoring of NSCLC patients.
机译：我们检查了非小细胞肺癌（NSCLC）患者化疗前后的血小板血管内皮生长因子（VEGF（PLT））和血清转化生长因子β1（TGF-beta 1）的水平，以评估其临床疗效价值作为生物标志物。 2012年7月至2013年10月在秦皇岛市第一医院招募了115名受试者，包括65名接受化疗的NSCLC患者（NSCLC组）和50名健康对照（对照组）。所有NSCLC患者均接受吉西他滨联合顺铂（GP方案），共两个疗程。使用酶联免疫吸附试验（ELISA）测定化疗前后的VEGF（PLT）和血清TGF-β1水平。使用雅培CD-1600自动血液分析仪获得血小板计数。根据化疗1周后的CT扫描结果，将NSCLC组分为完全缓解（CR）+部分缓解（PR）组和稳定疾病（SD）+进行性疾病（PD）组。我们的结果表明，与对照组相比，NSCLC组化疗前的VEGF（PLT）和血清TGF-β1水平显着高于对照组（VEGF（PLT）为0.813 +/- 0.072对0.547 +/- 0.024; t = 26.48; P <0.001和TGF-beta 1，46.00 +/- 4.47与16.43 +/- 2.12; t = 44.87; P <0.001）。重要的是，与化疗前相比，CR + PR组化疗后VEGF（PLT）和血清TGF-β1水平显着降低（VEGF（PLT），0.453 +/- 0.078 vs. 0.814 +/- 0.127; t = 15.51; P <0.001和TGF-beta 1，20.17 +/- 2.43与42.13 +/- 4.54; t = 27.31; P <0.001）。相比之下，SD + PD组的化疗后VEGF（PLT）和血清TGF-β1水平明显高于化疗前（VEGF（PLT），0.816 +/- 0.043对1.065 +/- 0.016; t = 22.38; P <0.001和TGF-beta 1，41.80 +/- 5.46与45.83 +/- 4.62; t = 2.32; P = 0. 03）。我们的结果表明，NSCLC患者表现出高的VEGF（PLT）和血清TGF-beta 1水平，而VEGF（PLT）和TGF-beta 1水平与GP方案的化疗反应相关。因此，VEGF（PLT）和血清TGF-beta 1水平是非小细胞肺癌患者临床监测中有价值的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号